Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Corcept Therapeutics Incorporated (CORT)
USD88.80
+2.90 (+3.38%)
US NASDAQ Healthcare Biotechnology
Address
149 Commonwealth Drive 94025
Menlo Park, CA, US
Menlo Park, CA, US
CEO
Joseph K. Belanoff
Website
corcept.com
IPO
2004-04-14
CIK 1088856 ISIN US2183521028
Also trades on
London Stock Exchange · 0I3Q.L (USD)
NASDAQ Capital Market · CORT (USD)
Description
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
News Sentiment (7d)
Based on only 2 articles — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD88.80
+2.90 (+3.38%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
0.46
Float Shares
88.86M
Free Float %
82.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.07% | -1.60% | +22.17% | +33.54% | -34.69% | +47.13% | -29.03% | +116.58% | +148.42% | +968.89% | +318.64% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (25 ratings, all time)
Buy
Price Targets & DCF
Current price
88.80
Low
30.00
-66.2%
Consensus
73.00
-17.8%
Median
81.50
-8.2%
High
100.00
+12.6%
DCF (Unlevered)
75.09
-15.4%
DCF (Levered)
115.51
+30.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
67% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 3 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 2 |
81.50
-8.2%
|
| Last Quarter | 3 |
76.67
-13.7%
|
| Last Year | 11 |
85.36
-3.9%
|
| All Time | 24 |
74.04
-16.6%
|
Quality scores
Altman Z-Score
21.41
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
7 / 10
Strong MOAT
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
5 / 5
High
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+12.8% ★ Q1'26: +4.9% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-33.3% Q1'26: -276.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+6.8% Q1'26: -10.3% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+5.9% ★ Q1'26: -30.1% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+15.9% ★ Q1'26: -44.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+5.7% Q1'26: -12.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.13× ★ Q1'26: -0.05× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 4 EPS Ana. |
Dec 2027 4 Rev. Ana. 4 EPS Ana. |
Dec 2028 5 Rev. Ana. 3 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
50.29M
est: 50.81M (-1.0%)
|
81.32M
est: 80.97M (+0.4%)
|
159.20M
est: 159.20M (+0.0%)
|
251.25M
est: 251.28M (0.0%)
|
306.49M
est: 306.26M (+0.1%)
|
353.87M
est: 358.48M (-1.3%)
|
365.98M
est: 367.75M (-0.5%)
|
401.86M
est: 403.88M (-0.5%)
|
482.38M
est: 569.61M (-15.3%)
|
675.04M
est: 692.67M (-2.5%)
|
761.41M
est: 816.17M (-6.7%)
|
957.43M
952.18M – 958.31M
+17.3% YoY
|
1.20B
1.11B – 1.37B
+25.8% YoY
|
1.57B
1.53B – 1.62B
+30.7% YoY
|
2.21B
1.99B – 2.45B
+40.2% YoY
|
2.68B
2.42B – 2.97B
+21.2% YoY
|
| EBITDA |
-3.29M
est: 14.54M (-122.6%)
|
10.27M
est: 23.17M (-55.7%)
|
52.96M
est: 50.96M (+3.9%)
|
89.73M
est: 99.90M (-10.2%)
|
113.78M
est: 122.63M (-7.2%)
|
130.44M
est: 130.03M (+0.3%)
|
127.95M
est: 99.74M (+28.3%)
|
113.89M
est: 130.43M (-12.7%)
|
108.32M
est: 128.02M (-15.4%)
|
138.29M
est: 155.68M (-11.2%)
|
46.69M
est: 183.44M (-74.5%)
|
215.19M
214.01M – 215.39M
+17.3% YoY
|
270.79M
250.43M – 307.44M
+25.8% YoY
|
353.94M
343.46M – 364.41M
+30.7% YoY
|
496.05M
448.13M – 551.40M
+40.2% YoY
|
601.23M
543.15M – 668.32M
+21.2% YoY
|
| EBIT |
-3.44M
est: 14.32M (-124.0%)
|
10.07M
est: 22.82M (-55.9%)
|
52.86M
est: 50.65M (+4.4%)
|
89.50M
est: 96.87M (-7.6%)
|
111.61M
est: 115.07M (-3.0%)
|
128.20M
est: 124.56M (+2.9%)
|
125.01M
est: 96.71M (+29.3%)
|
112.63M
est: 125.03M (-9.9%)
|
107.28M
est: 125.96M (-14.8%)
|
136.95M
est: 153.17M (-10.6%)
|
44.80M
est: 180.48M (-75.2%)
|
211.71M
210.55M – 211.91M
+17.3% YoY
|
266.42M
246.39M – 302.48M
+25.8% YoY
|
348.22M
337.92M – 358.53M
+30.7% YoY
|
488.05M
440.90M – 542.51M
+40.2% YoY
|
591.53M
534.39M – 657.54M
+21.2% YoY
|
| Net Income |
-6.41M
est: -11.35M (+43.5%)
|
8.14M
est: 4.54M (+79.3%)
|
129.12M
est: 131.37M (-1.7%)
|
75.41M
est: 81.33M (-7.3%)
|
94.18M
est: 97.69M (-3.6%)
|
106.01M
est: 103.37M (+2.6%)
|
112.51M
est: 90.08M (+24.9%)
|
101.42M
est: 107.54M (-5.7%)
|
106.14M
est: 147.59M (-28.1%)
|
139.73M
est: 167.65M (-16.6%)
|
99.65M
est: 112.11M (-11.1%)
|
83.98M
25.23M – 95.88M
-25.1% YoY
|
253.38M
39.71M – 313.29M
+201.7% YoY
|
412.74M
327.21M – 498.27M
+62.9% YoY
|
818.71M
715.89M – 937.47M
+98.4% YoY
|
1.12B
981.69M – 1.29B
+37.1% YoY
|
| SGA |
36.95M
est: 18.39M (+100.9%)
|
45.24M
est: 29.30M (+54.4%)
|
62.42M
est: 56.62M (+10.2%)
|
81.29M
est: 88.54M (-8.2%)
|
100.36M
est: 105.52M (-4.9%)
|
105.33M
est: 104.11M (+1.2%)
|
122.36M
est: 99.15M (+23.4%)
|
152.85M
est: 135.42M (+12.9%)
|
184.26M
est: 239.38M (-23.0%)
|
280.32M
est: 291.10M (-3.7%)
|
448.73M
est: 343.00M (+30.8%)
|
402.36M
400.16M – 402.73M
+17.3% YoY
|
506.33M
468.26M – 574.86M
+25.8% YoY
|
661.80M
642.22M – 681.38M
+30.7% YoY
|
927.53M
837.93M – 1.03B
+40.2% YoY
|
1.12B
1.02B – 1.25B
+21.2% YoY
|
| EPS |
-0.06
est: -0.10 (+40.0%)
|
0.07
est: 0.04 (+75.0%)
|
1.14
est: 0.43 (+166.7%)
|
0.60
est: 0.57 (+5.3%)
|
0.82
est: 0.80 (+2.1%)
|
0.92
est: 0.84 (+9.5%)
|
0.97
est: 0.89 (+8.6%)
|
0.95
est: 0.96 (-0.5%)
|
1.02
est: 1.22 (-16.3%)
|
1.35
est: 1.41 (-4.1%)
|
0.95
est: 0.96 (-0.6%)
|
0.50
0.21 – 0.80
-47.2% YoY
|
1.60
0.33 – 2.61
+217.0% YoY
|
3.22
2.73 – 4.15
+101.6% YoY
|
6.82
5.97 – 7.81
+111.6% YoY
|
9.36
8.18 – 10.71
+37.1% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-04 | HC Wainwright & Co. | Buy | Buy | Maintain |
| 2026-05-01 | Piper Sandler | Overweight | Overweight | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B | 3/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | B | 3/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | B | 3/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | B | 3/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | B | 3/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | B | 3/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-01 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-15 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
120.46M
OE per share TTM
0.98
Owner's Yield
2.25%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
0.8%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
64
Total invested
46.09M
Insider transactions (90d)
1
Beneficial owners (>5%)
23
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | (1) BlackRock, Inc. | 16.35M | 15.20% | — | — | — | — | HC | Delaware | 2023-01-20 | ↗ |
| 2 | John F. Donahue | 13.88M | 12.50% | — | 13.88M | — | 13.88M | IN | Citizenship or place of Organization | 2017-02-14 | ↗ |
| 3 | Federated Investors, Inc. | 12.62M | 11.06% | 12.62M | — | 12.62M | — | HC | Citizenship or place of Organization | 2018-02-14 | ↗ |
| 4 | Longitude Venture Partners L.P. | 10.96M | 9.87% | — | 10.96M | — | 10.00 | PN | Delaware | 2016-12-15 | ↗ |
| 5 | The Vanguard Group - 23-1945930 | 10.84M | 10.23% | — | 184.9K | 10.57M | 277.4K | IA | Pennsylvania | 2022-03-09 | ↗ |
| 6 | 13-5156620 | 8.29M | 7.25% | — | — | — | 8.29M | BD, IA | New York | 2020-02-07 | ↗ |
| 7 | 26-0385758 | 8.02M | 6.95% | 8.02M | — | 8.02M | — | IA | Delaware | 2022-02-11 | ↗ |
| 8 | Patrick G. Enright | 6.42M | 5.70% | 272.3K | 6.14M | 272.3K | 10.00 | IN | United States of America | 2017-03-22 | ↗ |
| 9 | Joseph K. Belanoff | 6.37M | 5.80% | 6.37M | — | 6.37M | — | IN | United States | 2022-02-11 | ↗ |
| 10 | Juliet Tammenoms Bakker | 6.32M | 5.60% | 171.6K | 6.14M | 171.6K | 10.00 | IN | United States of America | 2017-03-22 | ↗ |
| 11 | Longitude Capital Associates, L.P. | 5.84M | 5.20% | — | 5.84M | — | 10.00 | PN | Delaware | 2017-03-22 | ↗ |
| 12 | Longitude Capital Partners, LLC | 5.84M | 5.20% | — | 5.84M | — | 10.00 | OO | Delaware | 2017-03-22 | ↗ |
| 13 | Consonance Capman GP LLC | 5.78M | 5.06% | — | 5.78M | — | — | HC, OO | Delaware, USA | 2018-02-14 | ↗ |
| 14 | Mitchell Blutt | 5.78M | 5.06% | — | 5.78M | — | — | HC, IN | USA | 2018-02-14 | ↗ |
| 15 | Consonance Capital Management LP | 5.68M | 4.98% | — | 5.68M | — | — | IA, PN | Delaware USA | 2018-02-14 | ↗ |
| 16 | G. Leonard Baker, Jr. | 5.47M | 5.20% | 5.47M | — | 5.47M | — | IN | USA | 2022-02-14 | ↗ |
| 17 | Federated Hermes, Inc. | 5.22M | 4.55% | 5.22M | — | 5.22M | — | HC | Citizenship or place of Organization | 2020-04-09 | ↗ |
| 18 | J. Christopher Donahue | 5.22M | 4.55% | — | 5.22M | — | 5.22M | IN | Citizenship or place of Organization | 2020-04-09 | ↗ |
| 19 | Rhodora J. Donahue | 5.22M | 4.55% | — | 5.22M | — | 5.22M | IN | Citizenship or place of Organization | 2020-04-09 | ↗ |
| 20 | Thomas R. Donahue | 5.22M | 4.55% | — | 5.22M | — | 5.22M | IN | Citizenship or place of Organization | 2020-04-09 | ↗ |
| 21 | Voting Shares Irrevocable Trust | 5.22M | 4.55% | 5.22M | — | 5.22M | — | OO | Citizenship or place of Organization | 2020-04-09 | ↗ |
| 22 | BARCLAYS GLOBAL INVESTORS, NA. | 797.5K | 2.70% | 178.0K | 6.4K | 9.19M | 178.0K | BK | Pennsylvania | 2018-02-08 | ↗ |
| 23 | Consonance Capital Opportunity Fund Management LP | 101.3K | 0.09% | — | 101.3K | — | — | IA, PN | Delaware USA | 2018-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
64
-353 vs prev Q
New positions
11
Closed positions
340
Increased
24
Reduced
26
Put/Call ratio
0.00
Calls held
2.0K
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | BLACKROCK, INC. | 12.06M +14.4K (+0.1%) | 419.76M -581.5M (-58.1%) | 11.65% +0.077 pp | 0.01% -0.010 pp | USD46.27 -24.8% | 6 qtrs — |
| 2 | VANGUARD GROUP INC | 9.49M -42.2K (-0.4%) | 330.42M -462.2M (-58.3%) | 9.17% +0.009 pp | 0.00% -0.007 pp | USD16.75 +107.8% | 84 qtrs — |
| 3 | INGALLS & SNYDER LLC | 7.20M -502.9K (-6.5%) | 250.39M -389.4M (-60.9%) | 6.95% -0.445 pp | 9.19% -11.726 pp | USD10.86 +220.4% | 39 qtrs — |
| 4 | RENAISSANCE TECHNOLOGIES LLC | 5.76M -330.8K (-5.4%) | 200.40M -305.7M (-60.4%) | 5.56% -0.288 pp | 0.31% -0.357 pp | USD15.76 +120.8% | 44 qtrs — |
| 5 | PARALLEL ADVISORS, LLC | 3.88M +7.7K (+0.2%) | 134.99M -186.8M (-58.0%) | 3.75% +0.028 pp | 2.47% -3.422 pp | USD24.53 +41.9% | 27 qtrs — |
| 6 | STATE STREET CORP | 2.99M +15.7K (+0.5%) | 103.91M -143.0M (-57.9%) | 2.88% +0.031 pp | 0.00% -0.005 pp | USD15.42 +125.7% | 51 qtrs — |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 2.67M +734.6K (+38.0%) | 92.89M -68.6M (-42.5%) | 2.58% +0.720 pp | 0.01% -0.005 pp | USD28.88 +20.5% | 64 qtrs — |
| 8 | FMR LLC | 2.41M +212.7K (+9.7%) | 84.03M -99.0M (-54.1%) | 2.33% +0.217 pp | 0.00% -0.005 pp | USD53.99 -35.5% | 36 qtrs — |
| 9 | DIMENSIONAL FUND ADVISORS LP | 1.62M -272.1K (-14.4%) | 56.58M -100.7M (-64.0%) | 1.56% -0.253 pp | 0.01% -0.022 pp | USD20.22 +72.1% | 37 qtrs — |
| 10 | MORGAN STANLEY | 1.59M +405.1K (+34.1%) | 55.40M -43.2M (-43.8%) | 1.54% +0.397 pp | 0.00% -0.003 pp | USD40.65 -14.4% | 51 qtrs — |
| 11 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.06M -8.2K (-0.8%) | 36.96M -52.0M (-58.4%) | 1.03% -0.002 pp | 0.01% -0.009 pp | USD34.04 +2.2% | 57 qtrs — |
| 12 | TD ASSET MANAGEMENT INC | 994.8K +38.7K (+4.0%) | 34.62M -44.8M (-56.4%) | 0.96% +0.042 pp | 0.03% -0.037 pp | USD73.23 -52.5% | 3 qtrs — |
| 13 | AQR CAPITAL MANAGEMENT LLC | 887.9K -619.3K (-41.1%) | 30.90M -94.4M (-75.3%) | 0.86% -0.590 pp | 0.02% -0.064 pp | USD74.68 -53.4% | 48 qtrs — |
| 14 | CITADEL ADVISORS LLC | 863.1K +751.5K (+673.4%) | 30.03M +20.8M (+223.9%) | 0.83% +0.726 pp | 0.00% +0.003 pp | USD39.40 -11.7% | 16 qtrs — |
| 15 | JPMORGAN CHASE & CO | 834.4K -15.4K (-1.8%) | 29.04M -41.6M (-58.9%) | 0.81% -0.010 pp | 0.00% -0.002 pp | USD69.43 -49.9% | 37 qtrs — |
| 16 | INVESCO LTD. | 817.0K +84.4K (+11.5%) | 28.43M -32.5M (-53.3%) | 0.79% +0.085 pp | 0.00% -0.005 pp | USD60.37 -42.4% | 44 qtrs — |
| 17 | EPOCH INVESTMENT PARTNERS, INC. | 816.7K -30.5K (-3.6%) | 28.42M -42.0M (-59.6%) | 0.79% -0.025 pp | 0.16% -0.225 pp | USD74.34 -53.2% | 3 qtrs — |
| 18 | CERITY PARTNERS LLC | 755.3K -3.1K (-0.4%) | 26.28M -36.7M (-58.3%) | 0.73% +0.001 pp | 0.04% -0.064 pp | USD35.85 -2.9% | 10 qtrs — |
| 19 | NORGES BANK | 695.8K +695.8K (+100.0%) | 24.21M +24.2M (+100.0%) | 0.67% +0.672 pp | 0.00% +0.003 pp | USD34.80 +0.0% | 1 qtrs NEW |
| 20 | FIRST TRUST ADVISORS LP | 693.3K -26.9K (-3.7%) | 24.13M -35.7M (-59.7%) | 0.67% -0.022 pp | 0.02% -0.027 pp | USD40.50 -14.1% | 35 qtrs — |
| 21 | NORTHERN TRUST CORP | 629.1K -13.3K (-2.1%) | 21.89M -31.5M (-59.0%) | 0.61% -0.009 pp | 0.00% -0.004 pp | USD15.34 +126.9% | 51 qtrs — |
| 22 | BANK OF NEW YORK MELLON CORP | 581.7K -19.8K (-3.3%) | 20.24M -29.7M (-59.5%) | 0.56% -0.016 pp | 0.00% -0.006 pp | USD18.26 +90.6% | 63 qtrs — |
| 23 | ALLSPRING GLOBAL INVESTMENTS HOLDINGS, LLC | 508.0K +268.2K (+111.8%) | 19.40M -799.8K (-4.0%) | 0.49% +0.260 pp | 0.03% -0.001 pp | USD40.10 -13.2% | 17 qtrs — |
| 24 | BOSTON TRUST WALDEN CORP | 527.6K -34.6K (-6.2%) | 18.36M -28.4M (-60.7%) | 0.51% -0.031 pp | 0.14% -0.204 pp | USD22.62 +53.8% | 21 qtrs — |
| 25 | CLEARBRIDGE INVESTMENTS, LLC | 507.4K -654.5K (-56.3%) | 17.66M -78.9M (-81.7%) | 0.49% -0.626 pp | 0.01% -0.059 pp | USD62.34 -44.2% | 8 qtrs — |
| 26 | FRANKLIN RESOURCES INC | 468.2K -31.9K (-6.4%) | 16.29M -25.3M (-60.8%) | 0.45% -0.028 pp | 0.00% -0.006 pp | USD53.11 -34.5% | 15 qtrs — |
| 27 | PRINCIPAL FINANCIAL GROUP INC | 444.1K -77.4K (-14.8%) | 15.45M -27.9M (-64.3%) | 0.43% -0.072 pp | 0.01% -0.014 pp | USD21.85 +59.3% | 50 qtrs — |
| 28 | GOLDMAN SACHS GROUP INC | 431.0K +41.9K (+10.8%) | 15.00M -17.3M (-53.6%) | 0.42% +0.043 pp | 0.00% -0.002 pp | USD34.50 +0.9% | 43 qtrs — |
| 29 | UBS GROUP AG | 414.9K -135.1K (-24.6%) | 14.44M -31.3M (-68.4%) | 0.40% -0.128 pp | 0.00% -0.005 pp | USD78.77 -55.8% | 45 qtrs — |
| 30 | AMERIPRISE FINANCIAL INC | 411.2K +188.8K (+84.9%) | 14.31M -4.2M (-22.6%) | 0.40% +0.184 pp | 0.00% -0.001 pp | USD38.69 -10.1% | 34 qtrs — |
| 31 | CHECKPOINT CAPITAL L.P. | 401.4K +9.1K (+2.3%) | 13.97M -18.6M (-57.2%) | 0.39% +0.011 pp | 4.36% -6.561 pp | USD74.21 -53.1% | 4 qtrs — |
| 32 | PRICE T ROWE ASSOCIATES INC /MD/ | 384.2K +1.2K (+0.3%) | 13.37M -18.5M (-58.0%) | 0.37% +0.003 pp | 0.00% -0.002 pp | USD73.74 -52.8% | 21 qtrs — |
| 33 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 345.9K +144.9K (+72.1%) | 12.04M -4.7M (-27.9%) | 0.33% +0.141 pp | 0.00% -0.001 pp | USD37.37 -6.9% | 38 qtrs — |
| 34 | CAPTION MANAGEMENT, LLC | 329.5K +290.0K (+734.2%) | 11.47M +8.2M (+249.3%) | 0.32% +0.280 pp | 0.08% +0.053 pp | USD37.00 -5.9% | 10 qtrs — |
| 35 | PUBLIC SECTOR PENSION INVESTMENT BOARD | 324.0K -41.8K (-11.4%) | 11.28M -19.1M (-62.9%) | 0.31% -0.039 pp | 0.04% -0.074 pp | USD51.71 -32.7% | 33 qtrs — |
| 36 | FAS WEALTH PARTNERS, INC. | 310.0K +1.7K (+0.6%) | 10.79M -14.8M (-57.9%) | 0.30% +0.003 pp | 0.70% -1.038 pp | USD17.58 +98.0% | 24 qtrs — |
| 37 | BRIDGEWATER ASSOCIATES, LP | 279.0K -26.9K (-8.8%) | 9.71M -15.7M (-61.8%) | 0.27% -0.024 pp | 0.04% -0.064 pp | USD83.11 -58.1% | 2 qtrs — |
| 38 | JANE STREET GROUP, LLC | 272.3K +226.1K (+489.4%) | 9.48M +5.6M (+146.8%) | 0.26% +0.219 pp | 0.00% +0.001 pp | USD44.99 -22.6% | 6 qtrs — |
| 39 | BRAUN STACEY ASSOCIATES INC | 264.3K -16.4K (-5.8%) | 9.20M -14.1M (-60.6%) | 0.26% -0.014 pp | 0.30% -0.466 pp | USD62.62 -44.4% | 5 qtrs — |
| 40 | CAITONG INTERNATIONAL ASSET MANAGEMENT CO., LTD | 251.6K +251.6K (+100.0%) | 8.76M +8.8M (+100.0%) | 0.24% +0.243 pp | 2.13% +2.130 pp | USD34.80 +0.0% | 1 qtrs NEW |
| 41 | ABRDN PLC | 245.1K -14.0K (-5.4%) | 8.53M -13.0M (-60.4%) | 0.24% -0.012 pp | 0.01% -0.021 pp | USD35.57 -2.2% | 7 qtrs — |
| 42 | LEGAL & GENERAL GROUP PLC | 245.0K -41.8K (-14.6%) | 8.53M -15.3M (-64.2%) | 0.24% -0.039 pp | 0.00% -0.004 pp | USD24.21 +43.7% | 39 qtrs — |
| 43 | IKARIAN CAPITAL, LLC | 236.7K +236.7K (+100.0%) | 8.24M +8.2M (+100.0%) | 0.23% +0.229 pp | 0.64% +0.643 pp | USD34.80 +0.0% | 1 qtrs NEW |
| 44 | EMERALD ADVISERS, LLC | 232.7K +287.0 (+0.1%) | 8.10M -11.2M (-58.1%) | 0.22% +0.002 pp | 0.25% -0.370 pp | USD83.83 -58.5% | 4 qtrs — |
| 45 | BURNEY CO/ | 223.8K -6.9K (-3.0%) | 7.79M -11.4M (-59.4%) | 0.22% -0.006 pp | 0.24% -0.367 pp | USD25.09 +38.7% | 23 qtrs — |
| 46 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 221.4K -148.4K (-40.1%) | 7.71M -23.0M (-74.9%) | 0.21% -0.141 pp | 0.02% -0.077 pp | USD36.49 -4.6% | 18 qtrs — |
| 47 | KENNEDY CAPITAL MANAGEMENT LLC | 209.7K +79.8K (+61.4%) | 7.30M -3.5M (-32.4%) | 0.20% +0.078 pp | 0.15% -0.084 pp | USD59.67 -41.7% | 6 qtrs — |
| 48 | COOKSON PEIRCE & CO INC | 207.5K -3.8K (-1.8%) | 7.22M -10.3M (-58.9%) | 0.20% -0.003 pp | 0.30% -0.421 pp | USD104.31 -66.6% | 5 qtrs — |
| 49 | UBS ASSET MANAGEMENT AMERICAS INC | 205.1K +2.4K (+1.2%) | 7.14M -9.7M (-57.6%) | 0.20% +0.003 pp | 0.00% -0.002 pp | USD42.32 -17.8% | 43 qtrs — |
| 50 | NEWTYN MANAGEMENT, LLC | 200.0K +200.0K (+100.0%) | 6.96M +7.0M (+100.0%) | 0.19% +0.193 pp | 0.73% +0.731 pp | USD34.80 +0.0% | 1 qtrs NEW |
| 51 | HRT FINANCIAL LP | 198.5K +198.5K (+100.0%) | 6.91M +6.9M (+100.0%) | 0.19% +0.192 pp | 0.02% +0.022 pp | USD34.80 +0.0% | 5 qtrs — |
| 52 | EMERALD MUTUAL FUND ADVISERS TRUST | 194.3K +36.2K (+22.9%) | 6.76M -6.4M (-48.5%) | 0.19% +0.036 pp | 0.33% -0.349 pp | USD74.51 -53.3% | 4 qtrs — |
| 53 | SWISS NATIONAL BANK | 187.0K +2.0K (+1.1%) | 6.51M -8.9M (-57.7%) | 0.18% +0.003 pp | 0.00% -0.005 pp | USD14.98 +132.3% | 43 qtrs — |
| 54 | RHUMBLINE ADVISERS | 186.7K -1.5K (-0.8%) | 6.50M -9.1M (-58.5%) | 0.18% -0.001 pp | 0.01% -0.007 pp | USD15.89 +119.0% | 55 qtrs — |
| 55 | NUVEEN, LLC | 186.5K +— (+0.0%) | 6.49M -9.0M (-58.1%) | 0.18% +0.001 pp | 0.00% -0.002 pp | USD109.13 -68.1% | 4 qtrs — |
| 56 | HUDSON BAY CAPITAL MANAGEMENT LP | 185.8K +185.8K (+100.0%) | 6.47M +6.5M (+100.0%) | 0.18% +0.179 pp | 0.02% +0.021 pp | USD34.80 +0.0% | 3 qtrs — |
| 57 | NEUBERGER BERMAN GROUP LLC | 182.0K +131.8K (+262.5%) | 6.33M +2.2M (+51.8%) | 0.18% +0.128 pp | 0.00% +0.002 pp | USD39.09 -11.0% | 6 qtrs — |
| 58 | WALLEYE CAPITAL LLC | 180.4K +180.1K (+56,099.7%) | 6.28M +6.3M (+23,432.3%) | 0.17% +0.174 pp | 0.02% +0.019 pp | USD34.87 -0.2% | 7 qtrs — |
| 59 | D. E. SHAW & CO., INC. | 169.7K -414.4K (-71.0%) | 5.90M -42.6M (-87.8%) | 0.16% -0.397 pp | 0.00% -0.024 pp | USD27.02 +28.8% | 42 qtrs — |
| 60 | ROYCE & ASSOCIATES LP | 166.6K -2.0K (-1.2%) | 5.80M -8.2M (-58.6%) | 0.16% -0.001 pp | 0.06% -0.081 pp | USD23.18 +50.1% | 31 qtrs — |
| 61 | VAN ECK ASSOCIATES CORP | 161.0K +38.5K (+31.4%) | 5.60M -4.6M (-45.0%) | 0.16% +0.038 pp | 0.00% -0.005 pp | USD59.34 -41.4% | 5 qtrs — |
| 62 | TANG CAPITAL MANAGEMENT LLC | 156.8K +156.8K (+100.0%) | 5.46M +5.5M (+100.0%) | 0.15% +0.151 pp | 0.27% +0.270 pp | USD34.80 +0.0% | 1 qtrs NEW |
| 63 | JANUS HENDERSON GROUP PLC | 153.3K +111.6K (+267.9%) | 5.33M +1.9M (+54.1%) | 0.15% +0.108 pp | 0.00% +0.001 pp | USD32.69 +6.5% | 28 qtrs — |
| 64 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 149.8K -219.5K (-59.4%) | 5.21M -25.5M (-83.0%) | 0.14% -0.210 pp | 0.00% -0.016 pp | USD28.04 +24.1% | 13 qtrs — |
| 65 | BROWN CAPITAL MANAGEMENT LLC | 138.2K -101.9K (-42.4%) | 4.81M -15.1M (-75.9%) | 0.13% -0.097 pp | 0.39% -0.428 pp | USD83.11 -58.1% | 2 qtrs — |
| 66 | INTRINSIC EDGE CAPITAL MANAGEMENT LLC | 137.9K +26.0K (+23.2%) | 4.80M -4.5M (-48.4%) | 0.13% +0.026 pp | 0.86% -0.441 pp | USD38.92 -10.6% | 9 qtrs — |
| 67 | LIVFORSAKRINGSBOLAGET SKANDIA, OMSESIDIGT | 181.6K +106.0K (+140.2%) | 4.77M +1.4M (+43.3%) | 0.18% +0.103 pp | 0.19% +0.056 pp | USD51.17 -32.0% | 4 qtrs — |
| 68 | DIADEMA PARTNERS LP | 134.8K +108.3K (+408.7%) | 4.69M +2.5M (+113.0%) | 0.13% +0.105 pp | 0.81% +0.245 pp | USD50.41 -31.0% | 4 qtrs — |
| 69 | CANADA PENSION PLAN INVESTMENT BOARD | 124.4K -45.3K (-26.7%) | 4.33M -9.8M (-69.3%) | 0.12% -0.043 pp | 0.00% -0.007 pp | USD82.56 -57.8% | 5 qtrs — |
| 70 | NEW YORK STATE TEACHERS RETIREMENT SYSTEM | 118.6K -4.8K (-3.9%) | 4.13M -6.1M (-59.8%) | 0.11% -0.004 pp | 0.01% -0.012 pp | USD18.75 +85.6% | 33 qtrs — |
| 71 | TANAKA CAPITAL MANAGEMENT INC | 111.1K -125.0 (-0.1%) | 3.87M -5.4M (-58.2%) | 0.11% +0.001 pp | 7.05% -9.592 pp | USD83.11 -58.1% | 2 qtrs — |
| 72 | SIMPLEX TRADING, LLC | 109.3K +109.3K (+100.0%) | 3.80M +3.8M (+100.0%) | 0.11% +0.106 pp | 0.00% +0.002 pp | USD34.80 +0.0% | 1 qtrs NEW |
| 73 | MERCER GLOBAL ADVISORS INC /ADV | 101.0K -6.2K (-5.8%) | 3.52M -5.4M (-60.6%) | 0.10% -0.005 pp | 0.01% -0.010 pp | USD43.77 -20.5% | 23 qtrs — |
| 74 | CAPITAL FUND MANAGEMENT S.A. | 97.7K -62.8K (-39.1%) | 3.40M -9.9M (-74.5%) | 0.09% -0.060 pp | 0.01% -0.026 pp | USD57.19 -39.2% | 15 qtrs — |
| 75 | SEI INVESTMENTS CO | 94.8K +67.8K (+251.8%) | 3.30M +1.1M (+47.3%) | 0.09% +0.066 pp | 0.00% +0.001 pp | USD45.18 -23.0% | 16 qtrs — |
| 76 | S&T BANK/PA | 93.3K -18.1K (-16.2%) | 3.25M -6.0M (-64.9%) | 0.09% -0.017 pp | 1.03% -1.575 pp | USD15.53 +124.1% | 32 qtrs — |
| 77 | VERITION FUND MANAGEMENT LLC | 91.0K +88.4K (+3,371.9%) | 3.17M +3.0M (+1,353.8%) | 0.09% +0.085 pp | 0.01% +0.012 pp | USD36.19 -3.8% | 7 qtrs — |
| 78 | MAN GROUP PLC | 90.7K -81.9K (-47.4%) | 3.16M -11.2M (-78.0%) | 0.09% -0.078 pp | 0.01% -0.020 pp | USD73.30 -52.5% | 32 qtrs — |
| 79 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 90.0K -949.0 (-1.0%) | 3.13M -4.4M (-58.6%) | 0.09% 0.000 pp | 0.00% -0.005 pp | USD11.94 +191.5% | 52 qtrs — |
| 80 | PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. | 90.0K +90.0K (+100.0%) | 3.13M +3.1M (+100.0%) | 0.09% +0.087 pp | 0.29% +0.291 pp | USD34.80 +0.0% | 1 qtrs NEW |
| 81 | ALLIANZ ASSET MANAGEMENT GMBH | 89.9K -63.5K (-41.4%) | 3.13M -9.6M (-75.5%) | 0.09% -0.061 pp | 0.00% -0.011 pp | USD26.63 +30.7% | 13 qtrs — |
| 82 | MILLENNIUM MANAGEMENT LLC | 88.4K -87.2K (-49.6%) | 3.08M -11.5M (-78.9%) | 0.09% -0.083 pp | 0.00% -0.005 pp | USD36.82 -5.5% | 44 qtrs — |
| 83 | PRUDENTIAL FINANCIAL INC | 84.7K -2.8K (-3.2%) | 2.95M -4.3M (-59.5%) | 0.08% -0.002 pp | 0.00% -0.005 pp | USD16.92 +105.7% | 38 qtrs — |
| 84 | ILLINOIS MUNICIPAL RETIREMENT FUND | 84.0K -710.0 (-0.8%) | 2.92M -4.1M (-58.5%) | 0.08% 0.000 pp | 0.04% -0.053 pp | USD50.15 -30.6% | 10 qtrs — |
| 85 | BANK OF AMERICA CORP /DE/ | 83.7K -27.6K (-24.8%) | 2.91M -6.3M (-68.5%) | 0.08% -0.026 pp | 0.00% 0.000 pp | USD52.10 -33.2% | 44 qtrs — |
| 86 | ASSETMARK, INC | 82.1K +17.4K (+26.8%) | 2.86M -2.5M (-46.9%) | 0.08% +0.017 pp | 0.01% -0.006 pp | USD45.43 -23.4% | 23 qtrs — |
| 87 | GREAT WEST LIFE ASSURANCE CO /CAN/ | 81.9K -16.2K (-16.5%) | 2.85M -5.4M (-65.3%) | 0.08% -0.015 pp | 0.01% -0.007 pp | USD23.89 +45.7% | 39 qtrs — |
| 88 | XTX TOPCO LTD | 80.6K +80.6K (+100.0%) | 2.80M +2.8M (+100.0%) | 0.08% +0.078 pp | 0.07% +0.074 pp | USD34.80 +0.0% | 5 qtrs — |
| 89 | BESSEMER GROUP INC | 76.5K +75.9K (+12,065.5%) | 2.66M +2.6M (+4,924.5%) | 0.07% +0.073 pp | 0.00% +0.004 pp | USD35.05 -0.7% | 11 qtrs — |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.25
Bearish
Ratio by volume
0.43
Bearish
Buys
1
Sells
4
Shares acquired
20.0K
Shares disposed
47.0K
Cash buys
—
Cash sales
1.00
Net activity
-27,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-22 | WILSON JAMES N | Director | G-Gift | D | Common Stock | 2,000 | 0.00 | — | 1,095,532 | I | ↗ |
| 2026-04-07 | Guyer William | Officer | M-Exempt | D | Stock Option (right to buy) | 20,000 | 21.65 | 433.0K | 190,000 | D | ↗ |
| 2026-04-06 | WILSON JAMES N | Director | G-Gift | D | Common Stock | 5,000 | 0.00 | — | 1,097,532 | I | ↗ |
| 2026-03-25 | BELANOFF JOSEPH K | Director / Officer | S-Sale | D | Common Stock | 26,198 | 50.07 | 1.31M | 2,918,326 | I | ↗ |
| 2026-03-20 | WILSON JAMES N | Director | G-Gift | D | Common Stock | 4,000 | 0.00 | — | 1,102,532 | I | ↗ |
| 2026-03-20 | Guyer William | Officer | M-Exempt | D | Stock Option (right to buy) | 11,767 | 21.65 | 254.8K | 210,000 | D | ↗ |
| 2026-03-17 | BAKER G LEONARD JR | Director | P-Purchase | A | Common Stock | 75,782 | 33.00 | 2.50M | 1,122,413 | D | ↗ |
| 2026-03-13 | WILSON JAMES N | Director | G-Gift | D | Common Stock | 28,000 | 0.00 | — | 1,106,532 | I | ↗ |
| 2026-03-13 | MAHONEY DAVID L | Director | J-Other | A | Common Stock | 24,531 | 0.00 | — | 1,237,145 | I | ↗ |
| 2026-03-04 | Guyer William | Officer | M-Exempt | D | Stock Option (right to buy) | 8,233 | 21.65 | 178.2K | 221,767 | D | ↗ |
| 2026-03-03 | Robb Gary Charles | Officer | F-InKind | D | Common Stock | 121 | 35.97 | 4.4K | 79,503 | D | ↗ |
| 2026-03-03 | Mokari Atabak | Officer | F-InKind | D | Common Stock | 96 | 35.97 | 3.5K | 15,257 | D | ↗ |
| 2026-03-03 | Maduck Sean | Officer | F-InKind | D | Common Stock | 110 | 35.97 | 4.0K | 8,977 | D | ↗ |
| 2026-03-03 | Lyon Joseph Douglas | Officer | F-InKind | D | Common Stock | 89 | 35.97 | 3.2K | 11,230 | D | ↗ |
| 2026-03-02 | Robb Gary Charles | Officer | A-Award | A | Common Stock | 499 | 35.97 | 17.9K | 79,125 | D | ↗ |
| 2026-03-02 | Mokari Atabak | Officer | A-Award | A | Common Stock | 397 | 35.97 | 14.3K | 14,956 | D | ↗ |
| 2026-03-02 | Maduck Sean | Officer | A-Award | A | Common Stock | 454 | 0.00 | — | 9,087 | D | ↗ |
| 2026-03-02 | Lyon Joseph Douglas | Officer | A-Award | A | Common Stock | 398 | 35.97 | 14.3K | 10,921 | D | ↗ |
| 2026-03-02 | Guyer William | Officer | A-Award | A | Common Stock | 498 | 0.00 | — | 2,231 | D | ↗ |
| 2026-02-27 | Robb Gary Charles | Officer | A-Award | A | Stock Option (right to buy) | 140,000 | 35.70 | 5.00M | 140,000 | D | ↗ |
| 2026-02-27 | Mokari Atabak | Officer | A-Award | A | Stock Option (right to buy) | 140,000 | 35.70 | 5.00M | 140,000 | D | ↗ |
| 2026-02-27 | Maduck Sean | Officer | A-Award | A | Stock Option (right to buy) | 140,000 | 35.70 | 5.00M | 140,000 | D | ↗ |
| 2026-02-27 | Lyon Joseph Douglas | Officer | A-Award | A | Stock Option (right to buy) | 140,000 | 35.70 | 5.00M | 140,000 | D | ↗ |
| 2026-02-27 | Hunt Hazel | Officer | A-Award | A | Stock Option (right to buy) | 140,000 | 35.70 | 5.00M | 140,000 | D | ↗ |
| 2026-02-27 | Guyer William | Officer | A-Award | A | Stock Option (right to buy) | 140,000 | 35.70 | 5.00M | 140,000 | D | ↗ |
| 2026-02-27 | BELANOFF JOSEPH K | Director / Officer | A-Award | A | Stock Option (right to buy) | 460,000 | 35.70 | 16.42M | 460,000 | D | ↗ |
| 2026-02-24 | WILSON JAMES N | Director | F-InKind | D | Common Stock | 10,636 | 36.48 | 388.0K | 89,364 | D | ↗ |
| 2026-02-09 | Hunt Hazel | Officer | M-Exempt | A | Common Stock | 150,000 | 3.88 | 582.0K | 333,405 | D | ↗ |
| 2026-02-03 | Guyer William | Officer | S-Sale | D | Common Stock | 20,000 | 40.87 | 817.3K | 1,235 | D | ↗ |
| 2026-01-27 | BAKER G LEONARD JR | Director | M-Exempt | A | Common Stock | 30,000 | 15.15 | 454.5K | 1,095,262 | I | ↗ |
| 2026-01-08 | Maduck Sean | Officer | G-Gift | D | Common Stock | 34,000 | 0.00 | — | 5,147 | I | ↗ |
| 2026-01-06 | Guyer William | Officer | S-Sale | D | Common Stock | 20,000 | 35.18 | 703.7K | 1,235 | D | ↗ |
| 2026-01-01 | BAKER G LEONARD JR | Director | G-Gift | D | Common Stock | 0 | 0.00 | — | 3,308,303 | I | ↗ |
| 2025-12-24 | Robb Gary Charles | Officer | M-Exempt | A | Common Stock | 145,000 | 3.88 | 562.6K | 158,910 | D | ↗ |
| 2025-12-24 | BELANOFF JOSEPH K | Director / Officer | F-InKind | D | Common Stock | 306,846 | 83.59 | 25.65M | 243,154 | D | ↗ |
| 2025-12-12 | WILSON JAMES N | Director | G-Gift | D | Common Stock | 400,000 | 0.00 | — | 1,045,168 | I | ↗ |
| 2025-12-02 | Robb Gary Charles | Officer | F-InKind | D | Common Stock | 148 | 79.78 | 11.8K | 13,910 | D | ↗ |
| 2025-12-02 | Mokari Atabak | Officer | F-InKind | D | Common Stock | 118 | 79.78 | 9.4K | 14,559 | D | ↗ |
| 2025-12-02 | Maduck Sean | Officer | F-InKind | D | Common Stock | 135 | 79.78 | 10.8K | 8,179 | D | ↗ |
| 2025-12-02 | Lyon Joseph Douglas | Officer | F-InKind | D | Common Stock | 110 | 79.78 | 8.8K | 10,523 | D | ↗ |
| 2025-12-02 | Guyer William | Officer | M-Exempt | A | Common Stock | 20,000 | 21.65 | 433.0K | 21,235 | D | ↗ |
| 2025-12-01 | Robb Gary Charles | Officer | A-Award | A | Common Stock | 224 | 79.78 | 17.9K | 13,834 | D | ↗ |
| 2025-12-01 | Mokari Atabak | Officer | A-Award | A | Common Stock | 178 | 79.78 | 14.2K | 14,499 | D | ↗ |
| 2025-12-01 | Maduck Sean | Officer | S-Sale | D | Common Stock | 20,000 | 79.52 | 1.59M | 7,904 | D | ↗ |
| 2025-12-01 | Lyon Joseph Douglas | Officer | A-Award | A | Common Stock | 178 | 0.00 | — | 10,633 | D | ↗ |
| 2025-12-01 | Guyer William | Officer | A-Award | A | Common Stock | 224 | 79.78 | 17.9K | 224 | D | ↗ |
| 2025-12-01 | BELANOFF JOSEPH K | Director / Officer | S-Sale | D | Common Stock | 40,000 | 79.77 | 3.19M | 2,701,370 | I | ↗ |
| 2025-11-25 | Guyer William | Officer | S-Sale | D | Common Stock | 4,500 | 80.90 | 364.1K | 787 | D | ↗ |
| 2025-11-17 | Guyer William | Officer | G-Gift | D | Common Stock | 5,287 | 0.00 | — | 0 | D | ↗ |
| 2025-11-05 | Guyer William | Officer | M-Exempt | D | Stock option (right to buy) | 20,000 | 21.65 | 433.0K | 290,000 | D | ↗ |
| 2025-11-05 | BELANOFF JOSEPH K | Director / Officer | S-Sale | D | Common Stock | 10,837 | 75.14 | 814.3K | 2,744,960 | I | ↗ |
| 2025-11-03 | Maduck Sean | Officer | S-Sale | D | Common Stock | 20,000 | 73.99 | 1.48M | 7,904 | D | ↗ |
| 2025-11-03 | Lyon Joseph Douglas | Officer | M-Exempt | D | Stock option (right to buy) | 5,000 | 13.56 | 67.8K | 16,571 | D | ↗ |
| 2025-11-03 | BELANOFF JOSEPH K | Director / Officer | S-Sale | D | Common Stock | 11,218 | 74.08 | 831.0K | 2,770,152 | I | ↗ |
| 2025-10-10 | Swisher Daniel N JR | Director | M-Exempt | A | Common Stock | 2,200 | 14.08 | 31.0K | 2,200 | D | ↗ |
| 2025-10-07 | Guyer William | Officer | M-Exempt | D | Stock option (right to buy) | 20,000 | 21.65 | 433.0K | 310,000 | D | ↗ |
| 2025-10-01 | Maduck Sean | Officer | S-Sale | D | Common Stock | 16,394 | 85.06 | 1.39M | 10,551 | D | ↗ |
| 2025-10-01 | Lyon Joseph Douglas | Officer | S-Sale | D | Common Stock | 600 | 85.39 | 51.2K | 10,277 | D | ↗ |
| 2025-10-01 | BELANOFF JOSEPH K | Director / Officer | S-Sale | D | Common Stock | 3,194 | 85.67 | 273.6K | 2,781,370 | I | ↗ |
| 2025-09-19 | Guyer William | Officer | G-Gift | D | Common Stock | 200 | 0.00 | — | 5,287 | D | ↗ |
| 2025-09-10 | Swisher Daniel N JR | Director | M-Exempt | D | Stock option (right to buy) | 2,200 | 14.08 | 31.0K | 3,300 | D | ↗ |
| 2025-09-10 | Cannon Gillian | Director | G-Gift | D | Common Stock | 7,393 | 0.00 | — | 0 | D | ↗ |
| 2025-09-04 | Cannon Gillian | Director | M-Exempt | D | Stock option (right to buy) | 11,000 | 22.99 | 252.9K | 49,000 | D | ↗ |
| 2025-09-03 | Robb Gary Charles | Officer | F-InKind | D | Common Stock | 256 | 71.38 | 18.3K | 13,610 | D | ↗ |
| 2025-09-03 | Mokari Atabak | Officer | F-InKind | D | Common Stock | 144 | 71.38 | 10.3K | 14,321 | D | ↗ |
| 2025-09-03 | Maduck Sean | Officer | F-InKind | D | Common Stock | 233 | 71.38 | 16.6K | 7,904 | D | ↗ |
| 2025-09-03 | Lyon Joseph Douglas | Officer | F-InKind | D | Common Stock | 189 | 71.38 | 13.5K | 10,277 | D | ↗ |
| 2025-09-02 | Robb Gary Charles | Officer | A-Award | A | Common Stock | 251 | 0.00 | — | 13,866 | D | ↗ |
| 2025-09-02 | Mokari Atabak | Officer | A-Award | A | Common Stock | 200 | 71.38 | 14.3K | 14,265 | D | ↗ |
| 2025-09-02 | Maduck Sean | Officer | S-Sale | D | Common Stock | 4,930 | 70.84 | 349.2K | 7,681 | D | ↗ |
| 2025-09-02 | Lyon Joseph Douglas | Officer | M-Exempt | D | Stock option (right to buy) | 5,000 | 13.56 | 67.8K | 26,571 | D | ↗ |
| 2025-09-02 | Guyer William | Officer | M-Exempt | D | Stock option (right to buy) | 20,000 | 21.65 | 433.0K | 330,000 | D | ↗ |
| 2025-09-02 | BELANOFF JOSEPH K | Director / Officer | S-Sale | D | Common Stock | 39,300 | 70.52 | 2.77M | 2,822,070 | I | ↗ |
| 2025-08-22 | Robb Gary Charles | Officer | M-Exempt | D | Stock option (right to buy) | 5,000 | 3.88 | 19.4K | 145,000 | D | ↗ |
| 2025-08-11 | Swisher Daniel N JR | Director | M-Exempt | D | Stock option (right to buy) | 2,200 | 14.08 | 31.0K | 5,500 | D | ↗ |
| 2025-08-08 | Guyer William | Officer | S-Sale | D | Common Stock | 35,007 | 71.77 | 2.51M | 5,487 | D | ↗ |
| 2025-08-05 | Guyer William | Officer | M-Exempt | D | Stock option (right to buy) | 14 | 21.65 | 303.10 | 385,007 | D | ↗ |
| 2025-08-01 | Maduck Sean | Officer | S-Sale | D | Common Stock | 1,714 | 69.70 | 119.5K | 7,681 | D | ↗ |
| 2025-08-01 | Lyon Joseph Douglas | Officer | S-Sale | D | Common Stock | 5,823 | 67.51 | 393.1K | 10,066 | D | ↗ |
| 2025-08-01 | BELANOFF JOSEPH K | Director / Officer | S-Sale | D | Common Stock | 5,446 | 69.65 | 379.3K | 2,861,370 | I | ↗ |
| 2025-07-18 | Maduck Sean | Officer | M-Exempt | A | Common Stock | 473 | 5.05 | 2.4K | 18,178 | D | ↗ |
| 2025-07-18 | Lyon Joseph Douglas | Officer | M-Exempt | A | Common Stock | 200 | 13.56 | 2.7K | 10,266 | D | ↗ |
| 2025-07-18 | Guyer William | Officer | M-Exempt | D | Stock option (right to buy) | 500 | 21.65 | 10.8K | 385,021 | D | ↗ |
| 2025-07-17 | Maduck Sean | Officer | M-Exempt | A | Common Stock | 4,315 | 5.05 | 21.8K | 22,020 | D | ↗ |
| 2025-07-17 | Lyon Joseph Douglas | Officer | M-Exempt | D | Stock option (right to buy) | 3,877 | 13.56 | 52.6K | 37,594 | D | ↗ |
| 2025-07-17 | Guyer William | Officer | S-Sale | D | Common Stock | 4,379 | 73.48 | 321.8K | 5,487 | D | ↗ |
| 2025-07-17 | BELANOFF JOSEPH K | Director / Officer | S-Sale | D | Common Stock | 615 | 73.69 | 45.3K | 2,901,370 | I | ↗ |
| 2025-07-10 | Swisher Daniel N JR | Director | S-Sale | D | Common Stock | 2,200 | 71.08 | 156.4K | 0 | D | ↗ |
| 2025-07-03 | Maduck Sean | Officer | G-Gift | D | Common Stock | 40,000 | 0.00 | — | 59,717 | I | ↗ |
| 2025-07-01 | Maduck Sean | Officer | M-Exempt | D | Stock option (right to buy) | 205 | 5.05 | 1.0K | 61,781 | D | ↗ |
| 2025-07-01 | Lyon Joseph Douglas | Officer | S-Sale | D | Common Stock | 100 | 73.51 | 7.4K | 10,066 | D | ↗ |
| 2025-07-01 | Guyer William | Officer | M-Exempt | D | Stock option (right to buy) | 100 | 21.65 | 2.2K | 389,900 | D | ↗ |
| 2025-06-16 | Robb Gary Charles | Officer | S-Sale | D | Common Stock | 3,185 | 70.77 | 225.4K | 13,364 | D | ↗ |
| 2025-06-12 | Maduck Sean | Officer | J-Other | A | Common Stock | 10,024 | 0.00 | — | 99,717 | I | ↗ |
| 2025-06-10 | WILSON JAMES N | Director | A-Award | A | Stock option (right to buy) | 25,000 | 72.27 | 1.81M | 25,000 | D | ↗ |
| 2025-06-10 | Swisher Daniel N JR | Director | S-Sale | D | Common Stock | 2,200 | 70.61 | 155.3K | 0 | D | ↗ |
| 2025-06-10 | Park Kimberly | Director | A-Award | A | Stock option (right to buy) | 15,000 | 72.27 | 1.08M | 15,000 | D | ↗ |
| 2025-06-10 | Murray Joshua M. | Director | A-Award | A | Stock option (right to buy) | 15,000 | 72.27 | 1.08M | 15,000 | D | ↗ |
| 2025-06-10 | MAHONEY DAVID L | Director | A-Award | A | Stock option (right to buy) | 15,000 | 72.27 | 1.08M | 15,000 | D | ↗ |
| 2025-06-10 | Guyer William | Officer | S-Sale | D | Common Stock | 3,082 | 72.75 | 224.2K | 5,487 | D | ↗ |
| 2025-06-10 | Cannon Gillian | Director | A-Award | A | Stock option (right to buy) | 15,000 | 72.27 | 1.08M | 15,000 | D | ↗ |
| 2025-06-10 | BAKER G LEONARD JR | Director | A-Award | A | Stock Option (Right To Buy) | 15,000 | 72.27 | 1.08M | 15,000 | D | ↗ |
| 2025-06-10 | Alton Gregg H | Director | A-Award | A | Stock option (right to buy) | 15,000 | 72.27 | 1.08M | 15,000 | D | ↗ |
| 2025-06-03 | Robb Gary Charles | Officer | F-InKind | D | Common Stock | 651 | 71.68 | 46.7K | 16,549 | D | ↗ |
| 2025-06-03 | Mokari Atabak | Officer | F-InKind | D | Common Stock | 519 | 71.68 | 37.2K | 14,065 | D | ↗ |
| 2025-06-03 | Lyon Joseph Douglas | Officer | F-InKind | D | Common Stock | 441 | 71.68 | 31.6K | 10,066 | D | ↗ |
| 2025-06-02 | Robb Gary Charles | Officer | A-Award | A | Common Stock | 997 | 71.68 | 71.5K | 16,203 | D | ↗ |
| 2025-06-02 | Mokari Atabak | Officer | A-Award | A | Common Stock | 775 | 0.00 | — | 14,584 | D | ↗ |
| 2025-06-02 | Maduck Sean | Officer | M-Exempt | D | Stock option (right to buy) | 20,000 | 5.05 | 101.0K | 61,986 | D | ↗ |
| 2025-06-02 | Lyon Joseph Douglas | Officer | S-Sale | D | Common Stock | 4,438 | 77.97 | 346.0K | 9,751 | D | ↗ |
| 2025-06-02 | BELANOFF JOSEPH K | Director / Officer | S-Sale | D | Common Stock | 4,631 | 83.46 | 386.5K | 2,923,352 | I | ↗ |
| 2025-05-29 | Maduck Sean | Officer | M-Exempt | A | Common Stock | 10,000 | 3.88 | 38.8K | 25,929 | D | ↗ |
| 2025-05-20 | Robb Gary Charles | Officer | G-Gift | D | Common Stock | 1,380 | 0.00 | — | 15,206 | D | ↗ |
| 2025-05-16 | MAHONEY DAVID L | Director | S-Sale | D | Common Stock | 3,523 | 74.65 | 263.0K | 0 | D | ↗ |
| 2025-05-16 | Guyer William | Officer | M-Exempt | D | Stock option (right to buy) | 32,262 | 21.65 | 698.5K | 410,000 | D | ↗ |
| 2025-05-12 | Swisher Daniel N JR | Director | M-Exempt | D | Stock option (right to buy) | 400 | 14.08 | 5.6K | 12,100 | D | ↗ |
| 2025-05-06 | Guyer William | Officer | M-Exempt | A | Common Stock | 7,060 | 21.65 | 152.8K | 12,547 | D | ↗ |
| 2025-05-02 | Maduck Sean | Officer | M-Exempt | A | Common Stock | 26,554 | 5.05 | 134.1K | 112,176 | D | ↗ |
| 2025-05-02 | BELANOFF JOSEPH K | Director / Officer | S-Sale | D | Common Stock | 18,480 | 72.52 | 1.34M | 2,963,505 | I | ↗ |
| 2025-05-01 | Maduck Sean | Officer | S-Sale | D | Common Stock | 12,856 | 71.94 | 924.8K | 85,622 | D | ↗ |
| 2025-05-01 | Lyon Joseph Douglas | Officer | S-Sale | D | Common Stock | 9,350 | 71.96 | 672.8K | 9,009 | D | ↗ |
| 2025-04-10 | Swisher Daniel N JR | Director | M-Exempt | A | Common Stock | 2,200 | 12.13 | 26.7K | 2,200 | D | ↗ |
| 2025-04-01 | Maduck Sean | Officer | S-Sale | D | Common Stock | 590 | 114.55 | 67.6K | 85,622 | D | ↗ |
| 2025-04-01 | Lyon Joseph Douglas | Officer | M-Exempt | A | Common Stock | 650 | 13.56 | 8.8K | 9,659 | D | ↗ |
| 2025-04-01 | Guyer William | Officer | S-Sale | D | Common Stock | 678 | 114.51 | 77.6K | 5,487 | D | ↗ |
| 2025-04-01 | BELANOFF JOSEPH K | Director / Officer | S-Sale | D | Common Stock | 350 | 114.71 | 40.1K | 2,981,985 | I | ↗ |
| 2025-03-31 | Maduck Sean | Officer | S-Sale | D | Common Stock | 15,133 | 101.43 | 1.53M | 91,212 | D | ↗ |
| 2025-03-31 | Lyon Joseph Douglas | Officer | M-Exempt | D | Stock option (right to buy) | 40,000 | 15.82 | 632.8K | 0 | D | ↗ |
| 2025-03-31 | BELANOFF JOSEPH K | Director / Officer | S-Sale | D | Common Stock | 35,102 | 94.72 | 3.32M | 2,982,335 | I | ↗ |
| 2025-03-24 | Maduck Sean | Officer | S-Sale | D | Common Stock | 1,697 | 60.58 | 102.8K | 85,622 | D | ↗ |
| 2025-03-24 | Lyon Joseph Douglas | Officer | M-Exempt | D | Stock option (right to buy) | 421 | 13.56 | 5.7K | 91,571 | D | ↗ |
| 2025-03-24 | BELANOFF JOSEPH K | Director / Officer | S-Sale | D | Common Stock | 1,974 | 60.83 | 120.1K | 3,017,437 | I | ↗ |
| 2025-03-20 | Robb Gary Charles | Officer | G-Gift | A | Common Stock | 233 | 0.00 | — | 10,898 | I | ↗ |
| 2025-03-12 | Robb Gary Charles | Officer | G-Gift | A | Common Stock | 1,000 | 0.00 | — | 10,665 | I | ↗ |
| 2025-03-10 | Swisher Daniel N JR | Director | M-Exempt | A | Common Stock | 2,200 | 12.13 | 26.7K | 2,200 | D | ↗ |
| 2025-03-04 | Guyer William | Officer | M-Exempt | D | Stock option (right to buy) | 20,000 | 19.26 | 385.2K | 30,000 | D | ↗ |
| 2025-03-03 | Robb Gary Charles | Officer | A-Award | A | Common Stock | 292 | 0.00 | — | 23,490 | D | ↗ |
| 2025-03-03 | Mokari Atabak | Officer | F-InKind | D | Common Stock | 228 | 60.58 | 13.8K | 12,570 | D | ↗ |
| 2025-03-03 | Maduck Sean | Officer | F-InKind | D | Common Stock | 228 | 60.58 | 13.8K | 85,090 | D | ↗ |
| 2025-03-03 | Lyon Joseph Douglas | Officer | A-Award | A | Common Stock | 216 | 59.07 | 12.8K | 8,793 | D | ↗ |
| 2025-03-03 | BELANOFF JOSEPH K | Director / Officer | S-Sale | D | Common Stock | 2,924 | 60.91 | 178.1K | 3,019,411 | I | ↗ |
| 2025-02-28 | Robb Gary Charles | Officer | A-Award | A | Stock option (right to buy) | 140,000 | 60.58 | 8.48M | 140,000 | D | ↗ |
| 2025-02-28 | Mokari Atabak | Officer | A-Award | A | Stock option (right to buy) | 140,000 | 60.58 | 8.48M | 140,000 | D | ↗ |
| 2025-02-28 | Maduck Sean | Officer | A-Award | A | Stock option (right to buy) | 140,000 | 60.58 | 8.48M | 140,000 | D | ↗ |
| 2025-02-28 | Lyon Joseph Douglas | Officer | A-Award | A | Stock option (right to buy) | 140,000 | 60.58 | 8.48M | 140,000 | D | ↗ |
| 2025-02-28 | Hunt Hazel | Officer | A-Award | A | Stock Option (right to buy) | 140,000 | 60.58 | 8.48M | 140,000 | D | ↗ |
| 2025-02-28 | Guyer William | Officer | A-Award | A | Stock option (right to buy) | 140,000 | 60.58 | 8.48M | 140,000 | D | ↗ |
| 2025-02-28 | BELANOFF JOSEPH K | Director / Officer | A-Award | A | Stock option (right to buy) | 350,000 | 60.58 | 21.20M | 350,000 | D | ↗ |
| 2025-02-11 | Hunt Hazel | Officer | M-Exempt | A | Common Stock | 150,000 | 3.29 | 493.5K | 268,581 | D | ↗ |
| 2025-02-10 | Swisher Daniel N JR | Director | S-Sale | D | Common Stock | 2,200 | 68.08 | 149.8K | 0 | D | ↗ |
| 2025-02-03 | Maduck Sean | Officer | M-Exempt | D | Stock option (right to buy) | 8,014 | 5.05 | 40.5K | 141,986 | D | ↗ |
| 2025-02-03 | Lyon Joseph Douglas | Officer | S-Sale | D | Common Stock | 5,000 | 66.92 | 334.6K | 8,759 | D | ↗ |
| 2025-01-27 | WILSON JAMES N | Director | G-Gift | D | Common Stock | 7,800 | 0.00 | — | 1,445,168 | I | ↗ |
| 2025-01-27 | Robb Gary Charles | Officer | G-Gift | A | Common Stock | 313 | 0.00 | — | 11,211 | I | ↗ |
| 2025-01-22 | WILSON JAMES N | Director | G-Gift | D | Common Stock | 146,742 | 0.00 | — | 0 | D | ↗ |
| 2025-01-10 | Swisher Daniel N JR | Director | M-Exempt | A | Common Stock | 2,200 | 12.13 | 26.7K | 2,200 | D | ↗ |
| 2025-01-03 | Robb Gary Charles | Officer | M-Exempt | A | Common Stock | 3,037 | 3.29 | 10.0K | 23,156 | D | ↗ |
| 2025-01-02 | Robb Gary Charles | Officer | M-Exempt | D | Stock option (right to buy) | 11,000 | 3.29 | 36.2K | 3,037 | D | ↗ |
| 2025-01-02 | Maduck Sean | Officer | M-Exempt | D | Stock option (right to buy) | 20,000 | 3.88 | 77.6K | 21,986 | D | ↗ |
| 2025-01-02 | Lyon Joseph Douglas | Officer | M-Exempt | D | Stock option (right to buy) | 5,000 | 11.35 | 56.8K | 4,167 | D | ↗ |
| 2025-01-01 | BAKER G LEONARD JR | Director | G-Gift | D | Common Stock | 0 | 0.00 | — | 3,308,303 | I | ↗ |
| 2024-12-31 | BELANOFF JOSEPH K | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-12-27 | WILSON JAMES N | Director | G-Gift | D | Common Stock | 7,800 | 0.00 | — | 1,306,226 | I | ↗ |
| 2024-12-10 | Swisher Daniel N JR | Director | S-Sale | D | Common Stock | 2,200 | 59.46 | 130.8K | 0 | D | ↗ |
| 2024-12-02 | Robb Gary Charles | Officer | A-Award | A | Common Stock | 290 | 59.21 | 17.2K | 19,829 | D | ↗ |
| 2024-12-02 | Mokari Atabak | Officer | A-Award | A | Common Stock | 231 | 0.00 | — | 12,798 | D | ↗ |
| 2024-12-02 | Maduck Sean | Officer | F-InKind | D | Common Stock | 295 | 57.68 | 17.0K | 84,788 | D | ↗ |
| 2024-12-02 | Lyon Joseph Douglas | Officer | A-Award | A | Common Stock | 215 | 59.21 | 12.7K | 8,544 | D | ↗ |
| 2024-12-02 | Guyer William | Officer | F-InKind | D | Common Stock | 309 | 57.68 | 17.8K | 5,487 | D | ↗ |
| 2024-11-22 | Robb Gary Charles | Officer | S-Sale | D | Common Stock | 2,609 | 56.20 | 146.6K | 20,163 | D | ↗ |
| 2024-11-22 | Lyon Joseph Douglas | Officer | S-Sale | D | Common Stock | 1,411 | 56.72 | 80.0K | 8,494 | D | ↗ |
| 2024-11-11 | Swisher Daniel N JR | Director | S-Sale | D | Common Stock | 2,200 | 59.88 | 131.7K | 0 | D | ↗ |
| 2024-11-04 | Guyer William | Officer | M-Exempt | A | Common Stock | 3,394 | 21.65 | 73.5K | 9,190 | D | ↗ |
| 2024-11-01 | Guyer William | Officer | M-Exempt | A | Common Stock | 6,606 | 21.65 | 143.0K | 12,402 | D | ↗ |
| 2024-10-01 | Robb Gary Charles | Officer | M-Exempt | D | Stock option (right to buy) | 11,000 | 3.29 | 36.2K | 14,037 | D | ↗ |
| 2024-10-01 | Guyer William | Officer | S-Sale | D | Common Stock | 10,000 | 46.28 | 462.8K | 5,796 | D | ↗ |
| 2024-09-27 | Robb Gary Charles | Officer | G-Gift | A | Common Stock | 415 | 0.00 | — | 9,665 | I | ↗ |
| 2024-09-18 | Robb Gary Charles | Officer | G-Gift | D | Common Stock | 870 | 0.00 | — | 22,772 | — | ↗ |
| 2024-09-17 | Robb Gary Charles | Officer | G-Gift | D | Common Stock | 300 | 0.00 | — | 23,642 | — | ↗ |
| 2024-09-03 | Robb Gary Charles | Officer | A-Award | A | Common Stock | 503 | 34.26 | 17.2K | 23,439 | — | ↗ |
| 2024-09-03 | Mokari Atabak | Officer | A-Award | A | Common Stock | 400 | 0.00 | — | 12,518 | — | ↗ |
| 2024-09-03 | Maduck Sean | Officer | A-Award | A | Common Stock | 458 | 0.00 | — | 85,083 | — | ↗ |
| 2024-09-03 | Lyon Joseph Douglas | Officer | A-Award | A | Common Stock | 372 | 0.00 | — | 9,905 | — | ↗ |
| 2024-09-03 | Guyer William | Officer | M-Exempt | A | Common Stock | 10,000 | 21.65 | 216.5K | 16,039 | — | ↗ |
| 2024-08-26 | Robb Gary Charles | Officer | S-Sale | D | Common Stock | 3,101 | 35.71 | 110.7K | 23,190 | — | ↗ |
| 2024-08-01 | Swisher Daniel N JR | Director | M-Exempt | A | Common Stock | 150 | 5.86 | 879.00 | 150 | — | ↗ |
| 2024-08-01 | Hunt Hazel | Officer | M-Exempt | D | Stock Option (right to buy) | 60,000 | 2.81 | 168.6K | 0 | — | ↗ |
| 2024-08-01 | Guyer William | Officer | M-Exempt | D | Stock option (right to buy) | 10,000 | 21.65 | 216.5K | 480,000 | — | ↗ |
| 2024-07-31 | BELANOFF JOSEPH K | Director / Officer | M-Exempt | A | Common Stock | 450,000 | 3.29 | 1.48M | 798,811 | — | ↗ |
| 2024-07-01 | Swisher Daniel N JR | Director | M-Exempt | A | Common Stock | 2,200 | 5.86 | 12.9K | 2,200 | — | ↗ |
| 2024-07-01 | Robb Gary Charles | Officer | M-Exempt | A | Common Stock | 11,000 | 3.29 | 36.2K | 37,291 | — | ↗ |
| 2024-07-01 | Lyon Joseph Douglas | Officer | M-Exempt | A | Common Stock | 5,000 | 11.35 | 56.8K | 14,290 | — | ↗ |
| 2024-07-01 | Guyer William | Officer | M-Exempt | D | Stock option (right to buy) | 10,000 | 21.65 | 216.5K | 490,000 | — | ↗ |
| 2024-06-24 | Robb Gary Charles | Officer | J-Other | D | Common Stock | 1,000 | 0.00 | — | 6,700 | — | ↗ |
| 2024-06-04 | Robb Gary Charles | Officer | M-Exempt | A | Common Stock | 14,000 | 3.29 | 46.1K | 37,115 | — | ↗ |
| 2024-06-03 | Swisher Daniel N JR | Director | M-Exempt | D | Stock option (right to buy) | 2,200 | 5.86 | 12.9K | 2,350 | — | ↗ |
| 2024-06-03 | Robb Gary Charles | Officer | A-Award | A | Common Stock | 1,818 | 0.00 | — | 23,115 | — | ↗ |
| 2024-06-03 | Mokari Atabak | Officer | F-InKind | D | Common Stock | 571 | 30.17 | 17.2K | 8,965 | — | ↗ |
| 2024-06-03 | Maduck Sean | Officer | F-InKind | D | Common Stock | 823 | 30.17 | 24.8K | 84,399 | — | ↗ |
| 2024-06-03 | Lyon Joseph Douglas | Officer | M-Exempt | D | Stock option (right to buy) | 5,000 | 11.35 | 56.8K | 14,167 | — | ↗ |
Executive team
Top executives
EBIT / Employee
89.6K
Shares Outstanding
107.36M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Joseph K. Belanoff, M.D., Chief Executive Officer and President | 1.18M | 1.19M | — | 12.91M | — | 23.5K | 15.30M | 84.34% | ↗ |
| 2 | 2025 | Charles Robb, Chief Business Officer and Secretary | 711.4K | 358.0K | 124.5K | 5.16M | — | 23.5K | 6.38M | 82.87% | ↗ |
| 3 | 2025 | William Guyer, Pharm.D., Chief Development Officer | 706.4K | 429.6K | 17.9K | 5.16M | — | 23.5K | 6.34M | 81.71% | ↗ |
| 4 | 2025 | Sean Maduck, President Corcept Endocrinology | 648.9K | 261.2K | 112.0K | 5.16M | — | 23.5K | 6.21M | 84.96% | ↗ |
| 5 | 2025 | Atabak Mokari, Chief Financial Officer and Treasurer | 566.3K | 285.0K | 97.7K | 5.16M | — | 23.5K | 6.14M | 85.74% | ↗ |
| 6 | 2024 | Joseph K. Belanoff, M.D., Chief Executive Officer and President | 1.14M | 1.72M | — | 7.01M | — | 23.0K | 9.89M | 70.88% | ↗ |
| 7 | 2024 | Charles Robb, Chief Business Officer and Secretary | 686.3K | 533.6K | 91.3K | 2.80M | — | 23.0K | 4.14M | 69.97% | ↗ |
| 8 | 2024 | William Guyer, Pharm.D., Chief Development Officer | 656.2K | 510.2K | — | 2.80M | — | 23.0K | 3.99M | 70.22% | ↗ |
| 9 | 2024 | Sean Maduck, President Corcept Endocrinology | 626.1K | 471.1K | 46.7K | 2.80M | — | 23.0K | 3.97M | 71.79% | ↗ |
| 10 | 2024 | Atabak Mokari, Chief Financial Officer and Treasurer | 546.3K | 411.1K | 72.7K | 2.80M | — | 23.0K | 3.86M | 74.58% | ↗ |
| 11 | 2023 | Joseph K. Belanoff, M.D., Chief Executive Officer and President | 1.08M | 1.32M | — | 6.91M | — | 22.5K | 9.34M | 74.02% | ↗ |
| 12 | 2023 | Charles Robb, Chief Business Officer and | 659.3K | 397.2K | 112.9K | 2.76M | — | 22.5K | 3.96M | 72.73% | ↗ |
| 13 | 2023 | Charles Robb, Chief Business Officer and Secretary | 659.3K | 397.2K | 112.9K | 2.76M | — | 22.5K | 3.96M | 72.73% | ↗ |
| 14 | 2023 | Sean Maduck, President, Corcept Endocrinology | 601.6K | 422.8K | 97.3K | 2.76M | — | 22.5K | 3.91M | 73.22% | ↗ |
| 15 | 2023 | Sean Maduck, President Corcept Endocrinology | 601.6K | 422.8K | 97.3K | 2.76M | — | 22.5K | 3.91M | 73.22% | ↗ |
| 16 | 2023 | William Guyer, Pharm.D., Chief Development Officer | 628.2K | 379.8K | 60.9K | 2.76M | — | 22.6K | 3.86M | 73.28% | ↗ |
| 17 | 2023 | William Guyer, Pharm.D. Chief Development Officer | 628.2K | 379.8K | 60.9K | 2.76M | — | 22.6K | 3.86M | 73.28% | ↗ |
| 18 | 2023 | Atabak Mokari, Chief Financial Officer and Treasurer | 524.3K | 316.2K | 89.3K | 2.76M | — | 22.5K | 3.72M | 76.78% | ↗ |
| 19 | 2022 | Joseph K. Belanoff, M.D., Chief Executive Officer and President | 895.8K | 900.0K | — | 5.54M | — | 20.5K | 7.35M | 75.30% | ↗ |
| 20 | 2022 | Sean Maduck, President Corcept Endocrinology | 572.9K | 230.0K | 24.0K | 2.87M | — | 20.5K | 3.71M | 77.83% | ↗ |
| 21 | 2022 | Sean Maduck, President, Corcept Endocrinology | 572.9K | 230.0K | 24.0K | 2.87M | — | 20.5K | 3.71M | 77.83% | ↗ |
| 22 | 2022 | Charles Robb, Chief Business Officer and Secretary | 627.5K | 315.0K | 26.2K | 2.21M | — | 20.5K | 3.20M | 69.94% | ↗ |
| 23 | 2022 | Charles Robb, Chief Business Officer and | 627.5K | 315.0K | 26.2K | 2.21M | — | 20.5K | 3.20M | 69.94% | ↗ |
| 24 | 2022 | Hazel Hunt, Ph.D., Chief Scientific Officer | 572.9K | 316.3K | — | 2.21M | — | 6.0K | 3.11M | 71.21% | ↗ |
| 25 | 2022 | William Guyer, Pharm.D., Chief Development Officer | 572.9K | 345.0K | 24.0K | 1.11M | — | 20.5K | 2.07M | 54.66% | ↗ |
| 26 | 2022 | William Guyer, Pharm.D. Chief Development Officer | 572.9K | 345.0K | 24.0K | 1.11M | — | 20.5K | 2.07M | 54.66% | ↗ |
| 27 | 2022 | Atabak Mokari, Chief Financial Officer and Treasurer | 492.8K | 247.5K | 20.6K | 1.11M | — | 20.5K | 1.89M | 59.72% | ↗ |
| 28 | 2022 | Atabak Mokari, Chief Financial Officer | 492.8K | 247.5K | 20.6K | 1.11M | — | 20.5K | 1.89M | 59.72% | ↗ |
| 29 | 2021 | Joseph K. Belanoff, M.D., Chief Executive Officer and President | 843.8K | 850.0K | — | 9.29M | — | — | 10.98M | 84.58% | ↗ |
| 30 | 2021 | Atabak Mokari, Chief Financial Officer and Treasurer | 390.0K | 220.0K | — | 6.41M | — | — | 7.02M | 91.31% | ↗ |
| 31 | 2021 | Atabak Mokari, Chief Financial Officer | 390.0K | 220.0K | — | 6.41M | — | — | 7.02M | 91.31% | ↗ |
| 32 | 2021 | William Guyer, Pharm.D. Chief Development Officer | 206.7K | 247.5K | — | 6.09M | — | — | 6.55M | 93.06% | ↗ |
| 33 | 2021 | Charles Robb, Chief Business Officer and Secretary | 562.6K | 337.5K | — | 4.36M | — | — | 5.26M | 82.88% | ↗ |
| 34 | 2021 | Charles Robb, Chief Business Officer and | 562.6K | 337.5K | — | 4.36M | — | — | 5.26M | 82.88% | ↗ |
| 35 | 2021 | Hazel Hunt, Ph.D., Chief Scientific Officer | 517.3K | 309.4K | — | 3.72M | — | 6.7K | 4.55M | 81.68% | ↗ |
| 36 | 2021 | Sean Maduck, Chief Commercial Officer | 519.5K | 309.4K | — | 3.72M | — | — | 4.55M | 81.76% | ↗ |
| 37 | 2021 | Sean Maduck, President, Corcept Endocrinology | 519.5K | 309.4K | — | 3.72M | — | — | 4.55M | 81.76% | ↗ |
| 38 | 2020 | Joseph K. Belanoff, M.D., Chief Executive Officer and President | 769.6K | 744.0K | — | 4.24M | — | 10.9K | 5.76M | 73.54% | ↗ |
| 39 | 2020 | Sean Maduck, President, Corcept Endocrinology | 474.4K | 214.2K | — | 2.51M | — | — | 3.20M | 78.46% | ↗ |
| 40 | 2020 | Sean Maduck, Chief Commercial Officer | 474.4K | 214.2K | — | 2.51M | — | — | 3.20M | 78.46% | ↗ |
| 41 | 2020 | Charles Robb, Chief Business Officer and Secretary | 474.4K | 321.2K | — | 2.12M | — | — | 2.91M | 72.70% | ↗ |
| 42 | 2020 | Hazel Hunt, Ph.D., Chief Scientific Officer | 431.9K | 243.0K | — | 2.08M | — | 6.2K | 2.77M | 75.37% | ↗ |
| 43 | 2020 | Andreas Grauer, M.D., Chief Medical Officer | 454.6K | 219.2K | — | 1.27M | — | 118.3K | 2.06M | 61.62% | ↗ |
| 44 | 2019 | Joseph K. Belanoff, M.D., Chief Executive Officer and President | 707.5K | 745.3K | — | 3.51M | — | — | 4.96M | 70.70% | ↗ |
| 45 | 2019 | Andreas Grauer, M.D. Chief Medical Officer | 362.3K | 243.7K | — | 3.12M | — | 78.2K | 3.80M | 81.99% | ↗ |
| 46 | 2019 | Andreas Grauer, M.D., Chief Medical Officer | 362.3K | 243.7K | — | 3.12M | — | 78.2K | 3.80M | 81.99% | ↗ |
| 47 | 2019 | Charles Robb, Chief Business Officer and Secretary | 456.1K | 308.9K | — | 1.85M | — | — | 2.61M | 70.69% | ↗ |
| 48 | 2019 | Charles Robb, Chief Financial Officer and Secretary | 456.1K | 308.9K | — | 1.85M | — | — | 2.61M | 70.69% | ↗ |
| 49 | 2019 | Sean Maduck, Chief Commercial Officer | 456.1K | 308.9K | — | 1.48M | — | — | 2.24M | 65.87% | ↗ |
| 50 | 2019 | Sean Maduck, Senior Vice President, Commercial | 456.1K | 308.9K | — | 1.48M | — | — | 2.24M | 65.87% | ↗ |
| 51 | 2018 | Joseph K. Belanoff, M.D., Chief Executive Officer and President | 679.8K | 477.8K | — | 5.16M | — | — | 6.31M | 81.67% | ↗ |
| 52 | 2018 | Charles Robb, Chief Business Officer and Secretary | 436.7K | 237.6K | — | 2.17M | — | — | 2.85M | 76.31% | ↗ |
| 53 | 2018 | Charles Robb, Chief Financial Officer and Secretary | 436.7K | 237.6K | — | 2.17M | — | — | 2.85M | 76.31% | ↗ |
| 54 | 2018 | G. Charles Robb, Chief Financial Officer and Secretary | 436.7K | 237.6K | — | 2.17M | — | — | 2.85M | 76.31% | ↗ |
| 55 | 2018 | Sean Maduck, Senior Vice President, Commercial | 436.7K | 198.0K | — | 2.17M | — | — | 2.81M | 77.38% | ↗ |
| 56 | 2018 | Sean Maduck, Chief Commercial Officer | 436.7K | 198.0K | — | 2.17M | — | — | 2.81M | 77.38% | ↗ |
| 57 | 2018 | Robert S. Fishman, M.D. Former Chief Medical Officer | 444.2K | 200.5K | — | 1.63M | — | — | 2.27M | 71.64% | ↗ |
| 58 | 2017 | Joseph K. Belanoff, M.D., Chief Executive Officer and President | 647.3K | 702.0K | — | 2.92M | — | — | 4.27M | 68.41% | ↗ |
| 59 | 2017 | Sean Maduck, Senior Vice President, Commercial | 397.9K | 320.0K | — | 2.04M | — | — | 2.75M | 73.94% | ↗ |
| 60 | 2017 | G. Charles Robb, Chief Financial Officer and Secretary | 397.9K | 320.0K | — | 1.06M | — | — | 1.78M | 59.68% | ↗ |
| 61 | 2017 | Charles Robb, Chief Financial Officer and Secretary | 397.9K | 320.0K | — | 1.06M | — | — | 1.78M | 59.68% | ↗ |
| 62 | 2017 | Robert S. Fishman, M.D. Chief Medical Officer | — | 171.7K | — | 531.3K | — | — | 1.13M | 47.01% | ↗ |
| 63 | 2017 | Robert S. Fishman, M.D. Former Chief Medical Officer | 427.1K | 171.7K | — | 531.3K | — | — | 1.13M | 47.01% | ↗ |
| 64 | 2016 | Joseph K. Belanoff, M.D., Chief Executive Officer and President | 615.0K | 445.0K | — | 1.38M | — | — | 2.44M | 56.60% | ↗ |
| 65 | 2016 | G. Charles Robb, Chief Financial Officer and Secretary | 374.7K | 150.0K | — | 377.0K | — | — | 901.7K | 41.81% | ↗ |
| 66 | 2016 | Robert S. Fishman, M.D. Former Chief Medical Officer | 411.4K | 130.0K | — | 234.1K | — | — | 775.4K | 30.19% | ↗ |
| 67 | 2016 | Robert S. Fishman, M.D. Chief Medical Officer | — | 130.0K | — | 234.1K | — | — | 775.4K | 30.19% | ↗ |
| 68 | 2015 | Joseph K. Belanoff, M.D., Chief Executive Officer and President | — | 400.0K | — | — | — | — | 2.25M | 0.00% | ↗ |
| 69 | 2015 | Robert S. Fishman, M.D. Chief Medical Officer | — | 40.0K | — | — | — | — | 1.40M | 0.00% | ↗ |
| 70 | 2015 | G. Charles Robb, Chief Financial Officer and Secretary | — | 146.0K | — | — | — | — | 928.0K | 0.00% | ↗ |
| 71 | 2015 | Steven Lo, Former Senior Vice President, Oncology | 297.4K | — | — | 279.0K | — | — | 576.4K | 48.41% | ↗ |
| 72 | 2015 | Anne LeDoux, Former Vice President and Controller and Chief Accounting Officer | 145.6K | 65.0K | — | 49.0K | — | 12.3K | 271.9K | 18.02% | ↗ |
| 73 | 2014 | Joseph K. Belanoff, M.D., Chief Executive Officer and President | 571.3K | — | — | — | — | — | 571.3K | 0.00% | ↗ |
| 74 | 2014 | Joseph K. Belanoff, M.D., Chief Executive Officer and President | 571.3K | — | — | — | — | — | 571.3K | 0.00% | ↗ |
| 75 | 2014 | Anne LeDoux, Former Vice President and Controller and Chief Accounting Officer | 251.8K | — | — | 152.5K | — | — | 404.3K | 37.72% | ↗ |
| 76 | 2014 | Anne LeDoux, Vice President and Controller (Chief Accounting Officer) | 251.8K | — | — | 152.5K | — | — | 404.3K | 37.72% | ↗ |
| 77 | 2014 | Steven Lo, Senior Vice President, Oncology | 397.4K | — | — | — | — | — | 397.4K | 0.00% | ↗ |
| 78 | 2014 | Steven Lo, Former Senior Vice President, Oncology | 397.4K | — | — | — | — | — | 397.4K | 0.00% | ↗ |
| 79 | 2014 | G. Charles Robb, Chief Financial Officer and Secretary | 350.9K | — | — | — | — | — | 350.9K | 0.00% | ↗ |
| 80 | 2014 | G. Charles Robb, Chief Financial Officer and Secretary | 350.9K | — | — | — | — | — | 350.9K | 0.00% | ↗ |
| 81 | 2013 | Joseph K. Belanoff, M.D., Chief Executive Officer and President | 525.9K | 400.0K | — | 1.40M | — | — | 2.32M | 60.16% | ↗ |
| 82 | 2013 | Joseph K. Belanoff, M.D., Chief Executive Officer and President | 525.9K | 400.0K | — | 1.40M | — | — | 2.32M | 60.16% | ↗ |
| 83 | 2013 | Steven Lo, Former Senior Vice President, Oncology | 351.6K | 231.0K | — | 496.7K | — | — | 1.08M | 46.02% | ↗ |
| 84 | 2013 | Steven Lo, Senior Vice President and Chief Commercialization Officer | 351.6K | 231.0K | — | 496.7K | — | — | 1.08M | 46.02% | ↗ |
| 85 | 2013 | Steven Lo, Senior Vice President, Oncology | 351.6K | 231.0K | — | 496.7K | — | — | 1.08M | 46.02% | ↗ |
| 86 | 2013 | Robert L. Roe, M.D., President and Secretary (3 and 4) | 495.0K | 184.0K | — | 349.6K | — | 14.1K | 1.04M | 33.53% | ↗ |
| 87 | 2013 | G. Charles Robb, Chief Financial Officer and Secretary | 337.4K | 128.0K | — | 510.6K | — | — | 976.0K | 52.31% | ↗ |
| 88 | 2013 | G. Charles Robb, Chief Financial Officer | 337.4K | 128.0K | — | 510.6K | — | — | 976.0K | 52.31% | ↗ |
| 89 | 2013 | G. Charles Robb, Chief Financial Officer and Secretary | 337.4K | 128.0K | — | 510.6K | — | — | 976.0K | 52.31% | ↗ |
| 90 | 2013 | Anne LeDoux, Vice President and Controller (Chief Accounting Officer) | 243.2K | 85.0K | — | 174.8K | — | — | 503.0K | 34.75% | ↗ |
| 91 | 2013 | Anne M. LeDoux, Vice President and Controller (Chief Accounting Officer) | 243.2K | 85.0K | — | 174.8K | — | — | 503.0K | 34.75% | ↗ |
| 92 | 2013 | Anne LeDoux, Former Vice President and Controller and Chief Accounting Officer | 243.2K | 85.0K | — | 174.8K | — | — | 503.0K | 34.75% | ↗ |
| 93 | 2012 | Joseph K. Belanoff, M.D., Chief Executive Officer | 481.1K | 481.1K | — | — | — | — | 962.2K | 0.00% | ↗ |
| 94 | 2012 | Joseph K. Belanoff, M.D., Chief Executive Officer and President | 481.1K | 481.1K | — | — | — | — | 962.2K | 0.00% | ↗ |
| 95 | 2012 | Steven Lo, Senior Vice President and Chief Commercialization Officer | 318.3K | 159.1K | — | 453.4K | — | — | 930.8K | 48.71% | ↗ |
| 96 | 2012 | Steven Lo, Senior Vice President, Oncology | 318.3K | 159.1K | — | 453.4K | — | — | 930.8K | 48.71% | ↗ |
| 97 | 2012 | Steven Lo, Vice President of Commercial Operations | 318.3K | 159.1K | — | 453.4K | — | — | 930.8K | 48.71% | ↗ |
| 98 | 2012 | Robert L. Roe, M.D., President and Secretary (3 and 4) | 443.4K | 443.4K | — | — | — | — | 886.7K | 0.00% | ↗ |
| 99 | 2012 | Robert L. Roe, M.D., President | 443.4K | 443.4K | — | — | — | — | 886.7K | 0.00% | ↗ |
| 100 | 2012 | G. Charles Robb, Chief Financial Officer | 309.0K | 77.3K | — | — | — | — | 386.3K | 0.00% | ↗ |
| 101 | 2012 | G. Charles Robb, Chief Financial Officer and Secretary | 309.0K | 77.3K | — | — | — | — | 386.3K | 0.00% | ↗ |
| 102 | 2012 | G. Charles Robb, Chief Financial Officer | 309.0K | 77.3K | — | — | — | — | 386.3K | 0.00% | ↗ |
| 103 | 2012 | Anne LeDoux, Vice President and Controller (Chief Accounting Officer) | 234.1K | 70.2K | — | — | — | — | 304.3K | 0.00% | ↗ |
| 104 | 2012 | Anne M. LeDoux, Vice President and Controller (Chief Accounting Officer) | 234.1K | 70.2K | — | — | — | — | 304.3K | 0.00% | ↗ |
| 105 | 2012 | Anne LeDoux, Vice President and Controller (Chief Accounting Officer) | 234.1K | 70.2K | — | — | — | — | 304.3K | 0.00% | ↗ |
| 106 | 2011 | Joseph K. Belanoff, M.D., Chief Executive Officer and President | 467.1K | — | — | 3.06M | — | — | 3.52M | 86.75% | ↗ |
| 107 | 2011 | Joseph K. Belanoff, M.D., Chief Executive Officer | 467.1K | — | — | 3.06M | — | — | 3.52M | 86.75% | ↗ |
| 108 | 2011 | Robert L. Roe, M.D., President | 430.5K | — | — | 1.15M | — | — | 1.58M | 72.70% | ↗ |
| 109 | 2011 | Robert L. Roe, M.D., President and Secretary (3 and 4) | 430.5K | — | — | — | — | — | 1.58M | 0.00% | ↗ |
| 110 | 2011 | G. Charles Robb, Chief Financial Officer | 100.0K | — | — | 1.38M | — | — | 1.48M | 93.24% | ↗ |
| 111 | 2011 | G. Charles Robb, Chief Financial Officer | 100.0K | — | — | — | — | — | 1.48M | 0.00% | ↗ |
| 112 | 2011 | Anne LeDoux, Vice President and Controller (Chief Accounting Officer) | 227.3K | — | — | 382.1K | — | — | 609.4K | 62.70% | ↗ |
| 113 | 2011 | Anne M. LeDoux, Vice President and Controller (Chief Accounting Officer) | 227.3K | — | — | 382.1K | — | — | 609.4K | 62.70% | ↗ |
| 114 | 2011 | Steven Lo, Vice President of Commercial Operations | 309.0K | — | — | — | — | — | 309.0K | 0.00% | ↗ |
| 115 | 2011 | Steven Lo, Senior Vice President and Chief Commercialization Officer | 309.0K | — | — | — | — | — | 309.0K | 0.00% | ↗ |
| 116 | 2011 | Caroline M. Loewy, Chief Financial Officer | 177.5K | — | — | — | — | — | 177.5K | 0.00% | ↗ |
| 117 | 2010 | Steven Lo, Vice President of Commercial Operations | 88.6K | 25.0K | — | 1.08M | — | — | 1.20M | 90.51% | ↗ |
| 118 | 2010 | Joseph K. Belanoff, M.D., Chief Executive Officer | 453.5K | 454.0K | — | — | — | — | 907.5K | 0.00% | ↗ |
| 119 | 2010 | Joseph K. Belanoff, M.D., Chief Executive Officer | 453.5K | 454.0K | — | — | — | — | 907.5K | 0.00% | ↗ |
| 120 | 2010 | Robert L. Roe, M.D., President | 417.9K | 315.0K | — | — | — | 900.00 | 733.8K | 0.00% | ↗ |
| 121 | 2010 | Robert L. Roe, M.D., President | 417.9K | 315.0K | — | — | — | 900.00 | 733.8K | 0.00% | ↗ |
| 122 | 2010 | Caroline M. Loewy, Chief Financial Officer | 309.0K | 93.0K | — | — | — | — | 402.0K | 0.00% | ↗ |
| 123 | 2010 | Caroline M. Loewy, Chief Financial Officer | 309.0K | 93.0K | — | — | — | — | 402.0K | 0.00% | ↗ |
| 124 | 2010 | Anne LeDoux, Vice President and Controller (Chief Accounting Officer) | 220.7K | 66.0K | — | — | — | — | 286.7K | 0.00% | ↗ |
| 125 | 2010 | Anne LeDoux, Vice President and Controller (Chief Accounting Officer) | 220.7K | 66.0K | — | — | — | — | 286.7K | 0.00% | ↗ |
| 126 | 2009 | Joseph K. Belanoff, M.D., Chief Executive Officer | 440.3K | — | — | 989.5K | — | — | 1.43M | 69.21% | ↗ |
| 127 | 2009 | Joseph K. Belanoff, M.D., Chief Executive Officer | 440.3K | — | — | 909.4K | — | — | 1.35M | 67.38% | ↗ |
| 128 | 2009 | Robert L. Roe, M.D., President | 405.7K | — | — | 395.8K | — | 1.8K | 803.3K | 49.27% | ↗ |
| 129 | 2009 | Robert L. Roe, M.D., President | 405.7K | — | — | 363.7K | — | 1.8K | 771.3K | 47.16% | ↗ |
| 130 | 2009 | Anne LeDoux, Vice President and Controller | 214.2K | — | — | 113.6K | — | — | 327.8K | 34.65% | ↗ |
| 131 | 2009 | Anne LeDoux, Vice President and Controller (Chief Accounting Officer) | 214.2K | — | — | 113.6K | — | — | 327.8K | 34.65% | ↗ |
| 132 | 2009 | Anne LeDoux, Vice President and Controller (Chief Accounting Officer) | 214.2K | — | — | 113.6K | — | — | 327.8K | 34.65% | ↗ |
| 133 | 2009 | Caroline M. Loewy, Chief Financial Officer | 300.0K | — | — | — | — | — | 300.0K | 0.00% | ↗ |
| 134 | 2009 | Caroline M. Loewy, Chief Financial Officer | 300.0K | — | — | — | — | — | 300.0K | 0.00% | ↗ |
| 135 | 2008 | Joseph K. Belanoff, M.D., Chief Executive Officer | 427.4K | — | — | 282.5K | — | — | 709.9K | 39.79% | ↗ |
| 136 | 2008 | Caroline M. Loewy, Chief Financial Officer | 25.0K | — | — | 616.0K | — | — | 641.0K | 96.10% | ↗ |
| 137 | 2008 | Joseph K. Belanoff, M.D., Chief Executive Officer | 427.4K | — | — | — | — | — | 427.4K | 0.00% | ↗ |
| 138 | 2008 | Robert L. Roe, M.D., President | 393.9K | — | — | — | — | 900.00 | 394.8K | 0.00% | ↗ |
| 139 | 2008 | Anne LeDoux, Vice President and Controller | 208.0K | 20.8K | — | — | — | — | 228.8K | 0.00% | ↗ |
| 140 | 2008 | Anne LeDoux, Vice President and Controller (Chief Accounting Officer) | 208.0K | 20.8K | — | — | — | — | 228.8K | 0.00% | ↗ |
| 141 | 2008 | Caroline M. Loewy, Chief Financial Officer | 25.0K | — | — | 14.5K | — | — | 39.5K | 36.78% | ↗ |
| 142 | 2007 | Joseph K. Belanoff, M.D., Chief Executive Officer | 411.0K | 102.8K | — | 1.13M | — | — | 1.64M | 68.74% | ↗ |
| 143 | 2007 | Robert L. Roe, M.D., President | 378.8K | 95.3K | — | 285.6K | — | 2.4K | 762.0K | 37.47% | ↗ |
| 144 | 2007 | Joseph K. Belanoff, M.D., Chief Executive Officer | 411.0K | 102.8K | — | 200.1K | — | — | 713.9K | 28.03% | ↗ |
| 145 | 2007 | Anne LeDoux, Vice President and Controller | 191.8K | 47.9K | — | 141.3K | — | — | 381.0K | 37.08% | ↗ |
| 146 | 2007 | Fred Kurland, Chief Financial Officer | 93.4K | — | — | — | — | — | 93.4K | 0.00% | ↗ |
| 147 | 2006 | Robert L. Roe, M.D., President | 364.2K | — | — | — | — | 2.3K | 634.6K | 0.00% | ↗ |
| 148 | 2006 | Robert L. Roe, M.D., President | 364.2K | — | — | 181.5K | — | — | 545.7K | 33.26% | ↗ |
| 149 | 2006 | Joseph K. Belanoff, M.D., Chief Executive Officer | 395.2K | — | — | — | — | — | 395.2K | 0.00% | ↗ |
| 150 | 2006 | Joseph K. Belanoff, M.D., Chief Executive Officer | 395.2K | — | — | — | — | — | 395.2K | 0.00% | ↗ |
| 151 | 2006 | Fred Kurland, Chief Financial Officer | 257.1K | — | — | 90.8K | — | — | 347.8K | 26.09% | ↗ |
| 152 | 2006 | Fred Kurland, Chief Financial Officer | 257.1K | — | — | 90.8K | — | — | 347.8K | 26.09% | ↗ |
| 153 | 2006 | Anne LeDoux, Vice President and Controller | — | — | — | — | — | — | — | — | ↗ |
| 154 | 2005 | Joseph K. Belanoff, M.D. Chief Executive Officer | 379.2K | — | — | — | — | 2.3K | 381.5K | 0.00% | ↗ |
| 155 | 2005 | Robert L. Roe, M.D. President | 350.2K | — | — | — | — | 1.1K | 351.3K | 0.00% | ↗ |
| 156 | 2005 | Fred Kurland Chief Financial Officer | 247.2K | — | — | — | — | 2.3K | 249.5K | 0.00% | ↗ |
| 157 | 2004 | Joseph K. Belanoff, M.D. Chief Executive Officer | 341.6K | 34.2K | — | — | — | — | 375.7K | 0.00% | ↗ |
| 158 | 2004 | Joseph K. Belanoff, M.D. Chief Executive Officer | 341.6K | 34.2K | — | — | — | — | 375.7K | 0.00% | ↗ |
| 159 | 2004 | Robert L. Roe, M.D. President | 330.7K | 33.1K | — | — | — | — | 363.8K | 0.00% | ↗ |
| 160 | 2004 | Robert L. Roe, M.D. President | 330.7K | 33.1K | — | — | — | — | 363.8K | 0.00% | ↗ |
| 161 | 2004 | Fred Kurland Chief Financial Officer | 215.0K | 21.5K | — | — | — | — | 236.5K | 0.00% | ↗ |
| 162 | 2004 | Fred Kurland Chief Financial Officer | 215.0K | 21.5K | — | — | — | — | 236.5K | 0.00% | ↗ |
| 163 | 2003 | Joseph K. Belanoff, M.D. Chief Executive Officer | 310.5K | 31.1K | — | — | — | — | 341.6K | 0.00% | ↗ |
| 164 | 2003 | Robert L. Roe, M.D. President | 310.5K | 31.1K | — | — | — | — | 341.6K | 0.00% | ↗ |
| 165 | 2003 | Joseph K. Belanoff, M.D. Chief Executive Officer | 310.5K | 31.1K | — | — | — | — | 341.6K | 0.00% | ↗ |
| 166 | 2003 | Robert L. Roe, M.D. President | 310.5K | 31.1K | — | — | — | — | 341.6K | 0.00% | ↗ |
| 167 | 2003 | Fred Kurland Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 168 | 2003 | Fred Kurland Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
| Filing date | Form type | Filing |
|---|---|---|
| 2026-04-17 | DEF 14A | ↗ |
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Joseph K. Belanoff | Co-Founder, President, Chief Executive Officer & Director | 2M | — |
| William Guyer | Chief Development Officer | 1M | — |
| Gary Charles Robb | Chief Business Officer & Secretary | 1M | male |
| Sean Maduck | President of Endocrinology | 933.6K | male |
| Hazel Hunt | Chief Scientific Officer | 895.2K | — |
| Atabak Mokari | Chief Financial Officer & Treasurer | 874.8K | male |
| Amy Flood | Chief Human Resources & Communications Officer | — | female |
| Joseph Douglas Lyon | Chief Technology & Accounting Officer | — | male |
| Monica Tellado | President of Emerging Markets | — | female |
| Roberto W. Vieira | President of Oncology | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CORT
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
